192 related articles for article (PubMed ID: 27381386)
21. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.
Castanheira M; Huband MD; Mendes RE; Flamm RK
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652234
[TBL] [Abstract][Full Text] [Related]
22. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
Lomovskaya O; Sun D; Rubio-Aparicio D; Nelson K; Tsivkovski R; Griffith DC; Dudley MN
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848018
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects.
Griffith DC; Loutit JS; Morgan EE; Durso S; Dudley MN
Antimicrob Agents Chemother; 2016 Oct; 60(10):6326-32. PubMed ID: 27527080
[TBL] [Abstract][Full Text] [Related]
24. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.
Thaden JT; Pogue JM; Kaye KS
Virulence; 2017 May; 8(4):403-416. PubMed ID: 27384881
[TBL] [Abstract][Full Text] [Related]
25. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
26.
Hackel MA; Lomovskaya O; Dudley MN; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084745
[TBL] [Abstract][Full Text] [Related]
27. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
Falagas ME; Mavroudis AD; Vardakas KZ
Expert Rev Anti Infect Ther; 2016 Aug; 14(8):747-63. PubMed ID: 27400643
[TBL] [Abstract][Full Text] [Related]
28. Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.
Sun D; Rubio-Aparicio D; Nelson K; Dudley MN; Lomovskaya O
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 29038260
[TBL] [Abstract][Full Text] [Related]
29. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
Wright H; Bonomo RA; Paterson DL
Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690
[TBL] [Abstract][Full Text] [Related]
30. Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.
Weiss WJ; Pulse ME; Nguyen P; Peterson K; Silva J; Simecka JW; Valtierra D; Sabet M; Griffith DC
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038270
[TBL] [Abstract][Full Text] [Related]
31. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.
Sabet M; Tarazi Z; Nolan T; Parkinson J; Rubio-Aparicio D; Lomovskaya O; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109160
[TBL] [Abstract][Full Text] [Related]
32. Potency of Meropenem-Vaborbactam in Lung Surfactant.
Rubio-Aparicio D; Loutit J; Dudley M; Lomovskaya O
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038266
[TBL] [Abstract][Full Text] [Related]
33. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
[TBL] [Abstract][Full Text] [Related]
34. Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy.
Wong D; van Duin D
Drugs; 2017 Apr; 77(6):615-628. PubMed ID: 28303449
[TBL] [Abstract][Full Text] [Related]
35. Determination of MIC and disk diffusion quality control guidelines for meropenem-vaborbactam, a novel carbapenem/boronic acid β-lactamase inhibitor combination.
Munson E; Huband MD; Castanheira M; Fedler KA; Flamm RK
Diagn Microbiol Infect Dis; 2018 Apr; 90(4):324-328. PubMed ID: 29276104
[TBL] [Abstract][Full Text] [Related]
36. Meropenem/vaborbactam fixed combination for the treatment of patients with complicated urinary tract infections.
McCarthy MW; Walsh TJ
Drugs Today (Barc); 2017 Oct; 53(10):521-530. PubMed ID: 29286054
[TBL] [Abstract][Full Text] [Related]
37. Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.
Rubino CM; Bhavnani SM; Loutit JS; Lohse B; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311069
[TBL] [Abstract][Full Text] [Related]
38. Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination.
Cho JC; Zmarlicka MT; Shaeer KM; Pardo J
Ann Pharmacother; 2018 Aug; 52(8):769-779. PubMed ID: 29514462
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
[TBL] [Abstract][Full Text] [Related]
40. Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.
Jorgensen SCJ; Rybak MJ
Pharmacotherapy; 2018 Apr; 38(4):444-461. PubMed ID: 29427523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
